Investor Presentation Australian Equities Day

Australian
Equities Day
3 October 2025

•What is TruScreen
•The Global Market
•TruScreen’sTop Line
•Public Screening Programs
•FY 2026 Growth Strategy
•Revenue Outlook
•Appendix

What is TruScreen?

4
The Company manufactures two devices :
•one made in China for use in China, where locally
manufactured products have preferential market access
•one in Australia for other markets
For each patient screened with the TruScreen device a new
disposable Single Use Sensor (SUS) must be used.
This creates a recurring revenue model with a consumable
sale for each patient screened with TruScreen.
TruScreen Group Ltd is a revenue generating Life Science
company with a unique, AI-enabled real-time cervical
cancer screening device.

5
Handheld device (HHD)
Single Use Sensor (SUS)
How The TruScreen Device works
Intelligent Cradle

The Global Cervical
Cancer Screening
Market

7
Cervical Cancer Is A Global Public Health Issue
†
Around 660,000 new cases and
around 350,000 deaths in 2022
(WHO).
94% of global deaths occurred in
low and middle income countries
in 2022 (WHO).
Every 2 minutes, a
women dies from
cervical cancer.
Fourth most common cancer in
women worldwide, but preventable - in
fact only one of a handful of cancers
that we understand fully.
Most diagnoses
occur at working age
(35-44)
†
Cervical cancer (who.int)

8
WHO & 194 Countries are committed to eliminating Cervical Cancer
•In 2020 The World Health Organisation (WHO) and 194 member countries agreed on a strategy to eliminate
cervical cancer this century
90%
HPV Vaccination
coverage for girls by 15
years of age
70%
Screening coverage &
90% treatment of
precancerous lesions
90%
Management of
invasive cancer
cases
The WHO and member nations immediate commitment is to have screening coverage of 70% of women by
2030 – which TruScreen is well positioned to support.

9
TruScreen is WHO-recognised and positioned for growth
•TruScreen, as a stand-alone primary screening device has
regulatory approvals and distribution in 3 of the worlds 4 most
populous countries (India, China and Indonesia) and 2 of the
world’s 4 largest economies (China and India).
•WHO recognises Truscreen as an AI enabled device for cervical
cancer screening, including inviting TruScreen to participate in a
key meeting in Edinburgh in November 2024 to formulate policy
for AI enabled screening implementation.

10
It is projected to reachUSD 14.5 billionby 2033, an annual growth
rate of 5.8% (CAGR).
1
1
Zion Market Research
2
Custom Market Insights
*Women aged 15-64 years in the CIA World Fact Book :
https://www.cia.gov/the-world-factbook/
The Size of the Cervical Cancer Screening Market
2024
$7.9bn
2033
$14.5bn
Theglobal cervical cancer screening marketis valued at ~USD 7.9
billionin 2024
The market remains one of the most dynamic areas in preventive
women’s healthcare, with technology, government support, and
innovation driving its value higher each year.
2
TruScreen currently makes up just 0.02% of the total market
with enormous headroom for growth. In Low and Middle Income
Countries alone, there are 1bn+ women of screening age.*

11
Expansion of organized government
screening programs in emerging economies
TruScreen selected for Public Screening programs
in Zimbabwe, Vietnam, Uzbekistan and Eswatini
Key Drivers for Global Growth in
Cervical Cancer Screening
1
TruScreen Positioned to Capitalise on
these Drivers
1
Future Market Insights
Advances in AI and digital diagnostics
integrating into healthcare workflows
Strategic partnerships driving access and
awareness, especially in underserved
regions
Increased adoption of HPV-based testing
technologies
TruScreen is an AI enabled screening device using a
unique algorithm to identify abnormal cervical tissue
TruScreen deliberately targets underserved
emerging economies with little or no existing
screening infrastructure
TruScreen partnering with Dalton Hangzhou Bio
Science to distribute HPV testing products

TruScreen’s
Top Line

13
14
Countries with
regulatory approval
9
Regulatory
approvals in process
1000+
Healthcare professionals
trained
112
Hospitals / Clinics
using TruScreen
1m+
Women
Screened
232
Devices operational
worldwide
Clinical Performance
validations
30+
The Top Line
WHO and UNITAID
recognition

14
$
FY25 sales were NZ$ 1.7m,
comprised primarily from sales to
China
This result will be boosted in FY26 by major public
screening programs:
•Zimbabwe (program validation conducted Sept
2025)
•Vietnam (program launched April 2025, patient
recruitment and clinician screening training
commenced August 2025)
•Indonesia (registration achieved and first sale April
2025)
•Uzbekistan (registration achieved June 2025, and
pilot program MOU signed August 2025)
$
FY26 sales are forecast exceed NZ$ 2.8m,
making the Company monthly cash flow
positive in March 2026
FY26 revenue is forecast to be made up of revenue from our
largest market China, plus additional channels for which the
foundations were laid in FY25 – new distributors in Indonesia and
India, Public Screening Programs in Vietnam, Zimbabwe and
Uzbekistan, and our new strategic alliance with Dalton Bio.
Combined with the agreement to distribute Dalton Bioscience
HPV DNA equipment and kits, this represents significant product
and geographical diversification, broadening our business
operations.
The Top Line

15
Saudi Arabia study published with
sensitivity 83.3% and specificity
95% compared with Pap test of
66.7% and 98.2% respectively
Uzbekistan product registration completed to enable the validation
trial of TruScreen for a national cervical cancer screening program
COFEPRIS approval
for use in Mexico
Public Health system
Launch of a 5 year,
260,000 women cervical
cancer screening
program at Ho Chi Minh
City Public Health
Association
Indonesian distributor
appointed with commercial
sales commenced in a
significant addressable
market
Inclusion in Chinese Obstetricians
and Gynecologists Association
(COGA) Blue Book guideline and
China Society for Colposcopy and
Cervical Pathology (CSCCP)
guideline
Appointment of
distributor for India, the
world’s second most
populous country
Agreement on
validation protocol
for additional public
screening programs
in Zimbabwe
Appraisal by Baylor Foundation
from the US for a public screening
program in Eswatini
Global Recognition
Registration and Sales activity in Russia,
Kazakhstan, Kyrgyzstan, Armenia and Belarus
Europe CE mark held as
proof of quality and efficacy
The Top Line

16
•World Health Organisation (WHO)
•UNITAID
•Clinton Health Access Initiative
•Daffodil Foundation - Australia
•China Obstetricians and
Gynaecologists Association
•China Society for Colposcopy and
Cervical Pathology
•Russia Cervical Cancer Screening
Guideline
•Vietnam Hospital Technical List
•CE Mark, European Union
•NMPA, China
•TGA, Australia
•MHRA, UK
•SFDA, Saudi Arabia
•Roszdravnadzor, Russia
•COFEPRIS, Mexico
•WAND New Zealand
•Zimbabwe Ministry of Health
•IEAKI Indonesia
•Vietnam Technical List
•India (Test Licence)
•Uzbekistan
TruScreen Regulatory Approvals
•ISO 13485
•IEC 60601-1
•IEC 60601-1-2
•CE Mark
International Approvals:Recognized by
International Quality
Accreditation:
The Top Line

17
FY25 Medical Affairs achievements
•Included in UNITAID’s technology landscape report “Screening and treatment of pre-cancerous lesions for secondary
prevention of cervical cancer”, the only opto-electrical device included.
•Selected by StartUs Insights as one of six global companies that will have an impact on global wo m e n’s health.
•Invited to present at the WHO key meeting to further the use of AI technologies for screening of cervical cancer
Fudan University study
1
(n=1908), published by Springer Nature, concluded that TruScreen optoelectronic real time
screening detection accuracy outperformed liquid-based cytology (LBC) in patients with type 3 cervical transformation
zone.
Saudi Arabia study
2
(n=507) investigating Tr u S c ree n’s performance versus pap smears in cervical cancer detection
published and peer reviewed by BMC Women’s Health. Results showed that TruScreen demonstrated:
•High Sensitivity: TruScreen 83.3%, compared to Pap test 66.7%
•High Specificity: TruScreen 95%, compared to Pap test 98.2%
Beijing study
3
(n=100) from 2018 was published by Dovepress, demonstrating higher sensitivity (86.4%) and higher
specificity (74.4%) for screening cervical precancerous lesions in middle-aged women, compared to TCT and HR-HPV
tests. The study also demonstrated increased efficacy when used in combination with TCT and HPV tests and validates
TruScreen’s emerging markets growth strategy and recent agreement to distribute DaltonBio’s HPV IVD test products to
India.
OCT 24
NOV 24
APR 25
JUN 25
The Top Line

18
DaltonBio Strategic Alliance
1.TruScreen to be appointed a global distributor of DaltonBio HPV related IVD products (excluding U.S.A. and Canada).
2.DaltonBio to explore opportunities to assist sales of TruScreen’s AI enabled real time cervical screening device within its
distribution network, notably in its selected distributors in China and South America. DaltonBio have 200 sub distributors in
China which may augment TruScreen’s current distribution network in it’s largest market.
•Q4 FY25 - Memorandum of Understanding signed with Hangzhou
Dalton Bioscience (DaltonBio)
•Q1 FY26 - TruScreen and Dalton Bio sign Distribution Agreement for
HPV products in India
The collaboration will enhance access to innovative cervical cancer screening and detection solutions by leveraging the
technology strengths of both companies. As demonstrated in the COGA landmark study (2023) and Beijing Obstetrics and
Gynecology Hospital study (Dovepress, May 2025), co-testing improved TruScreen’s already impressive standalone sensitivity
significantly.
The Top Line

19
HumanPapillomavirus(HPV)NucleicAcidDetectionSystems
HPV Self Sampling Collection System
The DH3 kit is used to detect 14 high-risk HPV types
that cause cervical cancer, provides relative viral load
values, and it has clinical guiding significance for
screening high-risk groups of cervical precancerous
lesions.
DH3 can distinguish HPV-16/18 and achieve risk
stratification management. The hybrid capture
technology it applies does not require nucleic acid
extraction and amplification, and has exceptional
reproducibility and negative predictive value. The use of
HPV full-length probes can effectively avoid missed
diagnosis.
HPV tests-DH
TM
series by DaltonBio
14 High-risk
HPV types
18 High- & medium-risk
HPV types
The Top Line

Public Screening
Programs

21
•TruScreen’s sales to date have been
achieved largely through traditional sales
of devices and Single Use Sensors to
hospitals and clinics. In FY25 these
traditional channels made up 99% of
sales.
•In FY26, public screening programs are
expected to contribute greater than 20%
of total sales in FY26, with an increasing
percentage of sales expected from these
programs in future.
Entry into Public
Screening Programs

22
Vietnam
A 5-year program to screen 260,000 women
for cervical cancer using TruScreen in Ho
Chi Minh City launched in July 2025. The
program is a partnership between
TruScreen, Ho Chi Minh City Public Health
Association and distributor Gorton Health
Services, and will assist Vietnam to achieve
its goal of screening 60% of women aged 30
to 54 for cervical cancer (currently 25%).
April 12 2025. TruScreen Chair Tony Ho, President of the Ho
Chi Minh City Public Health Association Dr Le Truong Giang
and Managing Director of Gorton Health Services Mr An Trang
sign the formal agreement to conduct a 260,000 women
screening program in Ho Chi Minh City.

23
Zimbabwe
Since 2022, TruScreen has screened 14,000
women in the Masvingo Province, Zimbabwe,
through a public screening program
managed by the Zimbabwe National AIDS
Council (NAC) and the Ministry of Health and
Childcare. Re-validation will be completed in
September 2025 to recommence and
expand the program to the Harare and other
provinces - with 20,000 women expected to
be screened in FY26.
TruScreen’s Dr Carolina Velasquez training team in Zimbabwe, August 2025.

24
Uzbekistan
Following TruScreen’s receipt of regulatory
approval by the National Pharmaceutical
Safety Committee in Uzbekistan in June
2025, a 500 patient pilot project is planned
to commence in September/October in
Karakalpakstan, Uzbekistan. Uzbekistan
has over 11 million women of screening
age*, and is also a major healthcare
reference site for neighbouring Central
Asian nations.
TruScreen CEO Marty Dillon
signs MOU with Senator &
Professor Aral Ataniyazova
in Tashkent, Uzbekistan
The ‘Pilot Project for the use
of TruScreen‘in Uzbekistan
project team – Marty Dillon,
Dr Klara Yadgarova,Senator
& Professor Aral Ataniyazova
and Professor Asimidin
Kamilov

FY 2026 Strategy

26
Commercial Strategy
DIRECT
CHANNEL
THE INDIRECT CHANNEL
•Global distributors
THE DIRECT CHANNEL
•Major public screening programs
supported by national Ministries of
Health and Non-Government
Organisations – Vietnam, Uzbekistan and
Zimbabwe planned so far for FY26
PRODUCT PORTFOLIO EXPANSION
•Addition of market agreements to
distribute Hangzhou Dalton Bioscience
Limited’s HPV DNA tests and equipment
INDIRECT
CHANNEL
FY 2026 Strategy
PRODUCT PORTFOLIO EXPANSION

27
Key Objectives for FY2026
Development
of Indian
market
•Successful execution of PSPs
in Vietnam, Zimbabwe and
Uzbekistan
•Create an operating process
for success
•Continue development of the
growing public cervical cancer
screening sales channel with
key NGOs and Ministries of
Health
•Build Indonesia sales
with PT Mawar Mitra
Medika
•Work with Intega to
deliver sales in
Singapore, Malaysia
and Thailand
•Build on initial India
sales
•Sign new market
agreements
Dalton
sales
Development
of
Indonesian
and ASEAN
market
PSP
success
Monthly
cash flow
positive
in Mar 26
•Build sales with
Renovate (TRU and
Dalton)
FY 2026 Strategy

28
Key Enablers of Success
Strengthen
distributor
relationships
•Dalton relationship nurture,
including exploring opportunities
to grow TruScreen’s presence in
the Chinese market through
Dalton distribution network
•Public screening program
management
•MOH’s/NGO’s and Foundations
marketing
•Keep head count low
•Streamline internal
processes to create more
efficiencies in the day to day
- enable CEO to focus on
Sales more than admin
•Continue to seek SUS cost
improvements.
•Manufacturing and QA/Reg
software to lower consultant
costs.
•Investigate potential AI
contribution to efficiency
•Refine partner support
processes to deliver
maximum value – improve
marketing collateral and
sharing of information via
Quarterly distributor
meetings
•Refine pricing strategy to
suit market needs –
experiment with differential
pricing via selected support
programs
New BDM
hire
Marcomms
focus
Build
evidence
base and
international
recognition
•Website quality uplift and brand
refinement
•Social promotion of all activities
and successes in order to build
existing investor confidence
and attract new investors
•Collect marketing case studies
Continued
operational
cost-
effectiveness
•Get COGA paper published
and review interim data from
Uzbekistan and HPHA
•Build on International NGO
Recognition (WHO, UNITAID,
CHAI, COGA , CSCCP) to build
acceptance and remove
barriers to sale
HIRED AUGUST 2025
FY 2026 Strategy

Revenue Outlook

30
FY25 Sales (Actual)FY26 Sales (Forecast)
(+64% YOY increase with increased
diversification of revenue)
NZ$ 1.71mNZ$ 2.8m
Revenue Outlook

31
TruScreen Expected Sales Increase FY26
Six key
provinces
targeted;
Expected sales
increase >15%
> NZ$ 1.75m
Public Screening
Program to
resume;
Expected sales
> NZ$ 250k
Indonesia and
India sales
commence;
Expected sales
> NZ$ 250k
Dalton Bio IVD
HPV Test sales
to commence;
Expected sales
> NZ$ 200k
Ho Chi Minh City
Public Screening
Program to
commence and
hospital sales to
increase;
Expected sales
> NZ$ 150k
Public Screening
to commence;
Expected sales
> NZ$ 100k
Expected sales
> NZ$ 100k
NZ$ 2.8m
Revenue Outlook

32
China
•FY26 expectations are a 13% uptick on FY25 sales
•Distributor SWXT have forecast sales of 40 Devices and 150,000 SUS for FY 26
•Expected to represent ~60% of Global Sales – a ~30% reduction in our
reliance on China sales (87% in FY25), mitigating a key business risk
Vietnam
FY26 sales expectations underpinned by two key factors:
•Ho Chi Minh City Public Screening Program commenced August 2025
•Agreements from 6 major Ho Chi Minh City hospitals following the
inclusion in the Vietnam National technical list and Prof Campion’s
presentation at Tu Duc Hospital in Jan 2025
India
FY26 forecast is based upon the contracted Yr 1 of sales to new distributor
Renovate Biologicals, for which the first order has already been placed
(August 2025)
>NZ$1.75m
>NZ$150k
>NZ$150k
Revenue Outlook

33
Indonesia
FY26 forecast is based upon the contracted Year 1 of sales to new
distributor PT Mawar Mitra Medika, with first order already placed.
Uzbekistan
FY26 sales expectations underpinned by the commencement of 500-
patient pilot program in Karakalpakstan, Uzbekistan and potential for
expansion province by province.
Mexico
FY26 Forecast is based upon modest growth from FY25, building upon the
inclusion in the Mexico COFEPRIS approval for use in the public health
system in Mexico. Distributor Sunbird continues to engage with the newly
elected government officials to introduce TruScreen to the public health
sector, and are in advanced discussions with IMSS (the nation’s largest
public health insurer covering 38% of the population) for TruScreen
inclusion in their planned cervical cancer screening program
>NZ$100k
>NZ$100k
>NZ$100k
Revenue Outlook

34
Zimbabwe
FY26 forecast is based upon the recommencement of public screening
programs in metropolitan and regional Zimbabwe, once Ministry of Health
Re-Validation has been finalised in September 2025.
TruScreen is working with distributor INTEGA to introduce TruScreen into
this region. Documents have been supplied to commence the registration of
TruScreen in these countries and a key opinion leader, Dr Quek Swee
Cheong has agreed to use TruScreen both in his private clinic and programs
conducted by him in India and Nepal.
Dalton Bio
FY26 sales expectations expected to account for ~7% of sales in FY26.
The first formal distribution agreement was signed in May 2025, for
TruScreen to distribute DaltonBio’s HPV detection products in India, and the
first order has already been placed.
Singapore,
Malaysia and
Thailand
>NZ$250k
>NZ$200k
Revenue Outlook

Thank you.
Guy Robertson
Chief Financial Officer

M – +61 407 983 270
E – guyrobertson@truscreen.com
Martin Dillon
CEO
M - +61 449 115 065
E – martindillon@truscreen.com
TruScreen
Suite 3.03 18 Orion Rd
Lane Cove West NSW 2066
Australia
www.truscreen.com

Appendix

The TruScreen
Technology

38
a pen-like wand covered by a
Single Use Sensor (SUS) is used
to gently touch multiple spots on
the cervix. The SUS contains a
precision lens and electrodes
which interfaces with the cervix.
It sends and picks up low level
electrical and optical signals (14
readings per second) from the
cervical tissue.
1
How it works

39
The TruScreen Handheld Device (HHD) then applies
an integrated AI-enabled algorithm to analyse these
signals and compares them to an integrated
database of 2,000 patients drawn from a wide range
of geographic and ethnic backgrounds with differing
histological diagnoses.
This identifies the presence of abnormal (cancerous
and pre-cancerous) cells in the cervix and provides
physicians with real-time results.
2
How it works

40
Clinicians/physicians are able to immediately plan
appropri ate patient care
Device has an expected life span of 5–7 years
Disposable SUS is used once per test per patient -
ensures there is no chance of cross-infection
between patients
The entire patient data collection and analysis is
self- checked and controlled. No tissue sample
needs to be taken. These measures ensure that the
results are reliable and consistent, and that the
examination is painless and safe
TruScreen has been used on over 1 million women
and there has never been a single adverse event
reported

41
Why TruScreen?
TruscreenLiquid Based Cytology (LBC)HPV DNA
Real time results
Low infrastructure
costs
Strong clinical results
Objective results
Low training threshold
Portable
No cell or tissue
samples taken

42
•TruScreen specificity surpassed Liquid Based Cytology (LBC) and hrHPV
•TruScreen determined to be a simple, effective and rapid real-time cervical cancer screening method
•TruScreen determined to be an appropriate primary cervical cancer screening tool in regions with high morbidity and mortality to cervical cancer
•Also highlighted the superiority of TruScreen against alternative screening methods as well as the potential benefits of a TruScreen-HPV co-
testing. The size of the COGA study, which was TruScreen’s largest clinical evaluation to date, lends extra significance to its results and broad
conclusions.
TruScreen’s
sensitivity
was well above that for LBC
(87.5% v’s 66.5%), with a high
degree of statistical
significance (p<0.001).
TruScreen’s
specificity
(88.4%) was higher than both
LBC (86.3%) and hrHPV
testing (78.3%) (also at
p<0.001).
The sensitivity of TruScreen-hrHPV co-
testing (carrying out with multiple types
of screening tests at the same time, as
opposed to a single type) was higher than
that of LBC-hrHPV co-testing,
98.4% vs 95.9%
(statistically significant at p=0.006).
COGA Trial (n= 15,661, 2018-2021)

These results were presented at a research conference organised by ASCCP (American Society of Colposcopy and Cervical Pathology) in San Diego, USA in 2021.
The COGA trial manuscript is currently being reviewed for publishing in the Journal of the American Medical Association (JAMA).

43
2025 & BeyondBuilding for the Future 2020-2024
Building the Fundamentals 2014 - 2020
The TruScreen Journey
•China Growth continues
•Distribution of Dalton Bio IVD HPV DNA
products
•Vietnam HPHA program targets 260,000
women, Uzbekistan and Zimbabwe screening
programs to commence
•Indonesia and ASEAN commence
commercial use
•Global focus on AI boosts recognition of
TruScreen
2018 Oct
523% sales
growth in H1
2019 May
Recognition by
World Health
Organization
2020 Jan
ASX Listing
2014Nov
Listingon NZAX
2023-24
•COGA Blue Book and CSCCP Guidelines include TruScreen
•UNITAID recognises TruScreen’s value for Cervical Cancer screening
•WHO invited TruScreen to participate in Key AI meeting for cervical cancer screening
•Vietnam – HPHA large scale screening MOU signed
2018 Jul
Comence large scale
pilot programs in China
with CDC and COG
2018 Dec
Migration to NZX
2022
•Managing COVID-19 challenges
•Cost reduction
•Manufacturing and business
development in China
•Completion of major COGA study
•Strengthen distributor arrangement in
Vietnam
2017 Dec
CFDA (NMPA)
approval for
second generation
device

The TruScreen Te a m

45
The Board
A Director and Chairman of a number of
listed ASX companies.
Previous Executive Director of sales and
distribution company Arthur Ya t e s & Co
Limited, as well as Finance Director and
CFO of listed ASX retailers M. S. McLeod
Holdings Limited (Downtown Duty Free),
Galore Group Limited (Barbeques
Galore) and Brazin Limited (Bras N
Things, Sanity Music).
An experienced business executive and
has acted in a number of management
roles including 20 years as a senior
partner of KPMG and its predecessor
firms. Director of a number of private
companies across a broad range of
business activities including corporate
advisory, financial services, and funds
management. UNSW Commerce
graduate and Fellow of Chartered
Accountants Australia and New Zealand
Mr. Anthony Ho
B. Com (UNSW), CA, FAICD, FCIS, FGIA
Non-executive Chairman
Mr. Christopher Horn
B. Com (UNSW), FCA
Non-executive Independent Director
Experienced medical device engineer and
specialist in product R+D. Research and
Development Manager of the respiratory
humidification division of ASX/NZX-listed
Fisher & Paykel Healthcare. Brings 20
years’ experience in manufacturing,
working with suppliers across the globe.
His technical background in opto-
electronics and expertise in medical
device engineering is highly relevant to
TruScreen, w h o’s cervical cancer
screening device harnesses opto-
electronic signatures for screening results.
Dr. Dexter Cheung
B. Tech (Hons), M.Eng, PHD
Non-executive Director
Christine Pears
B. Com (Auck), CA, MinstD (NZ)
Non-executive Director
An experienced director and senior
executive leader. Independent Chair of
Franklin Vets and YMCA North Inc,
Independent Director of McKay Limited
and a member of the National Council of
YMCA New Zealand.
Has held Independent Director and CEO
roles with entities that establish and grow
domestic and international markets both
through distributors and directly. A
Chartered Accountant and member of the
Institute of Directors New Zealand.

46
The Executive Team
Guy Robertson, B. Com (Hons.) CA
CFO & Company Secretary
Martin Dillon skilfully managed the c o m p a ny ’s
listing on the NZX and oversees its strategic
vision. With over 30 years of commercial
experience, he has engaged with health and
regulatory authorities worldwide and held
numerous senior executive roles in private and
public companies in healthcare, advertising and
marketing.
Martin Dillon
CEO
Guy is an experienced finance executive, having held
the positions of Director, Company Secretary and
Chief Financial Officer of both private and ASX-listed
companies in Australia and Hong Kong. Guy held
senior roles in the Jardine Matheson Group of
Companies, including General Manager Finance of
Franklins Limited, Chief Operating Officer of Colliers
International Asia Pacific and Managing Director
(NSW) Jardine Lloyd Thompson.
Dr. Ta n has extensive knowledge of the TruScreen
product and has been involved in establishing key
markets in China, Vietnam, Mexico and Indonesia.
Dr Ta n is a qualified gynaecologist and has been
working withopto-electric screening technology for
over two decades and has led the
commercialisation of TruScreen since the
c o m p a n y ’s establishment in 2013.He oversees
global commercial operations.
Dr Jerry Tan
B. Med (Clinical), M.Com, CPA
General Manager Commercial

47
Dr Carolina Velasquez gained her Bachelor of
Medicine and Surgery at Pontificia Universidad in
Colombia and her Masters in Clinical Research at
Monash University in Melbourne . She has 8 years
experience with Truscreen conducting operator
training and supervising clinical trials in Australia,
India, Zimbabwe, China, Vietnam, Indonesia and
Mexico. Dr Velasquez also co-ordinates the work of
both Truscreen's Medical Advisory Committee and
international Medical Experts Group.
Usha is an experienced engineer with a strong background in
process development and manufacturing, across medical
devices, printhead and semiconductor technologies. With a
strong focus on continuous improvement and lean
manufacturing, she has successfully transitioned
prototypes to scalable production and trained international
teams. She is passionate in delivering high quality product,
through engineering excellence. Usha oversees TruScreen
device production, supporting R&D projects and lead
Service & Repair and field issues globally
Dr Carolina Velasquez
MBBS, M ClinRes
Medical Affairs and Training Manager
Usharani Raji
B Eng (Hons), MSc
Production Manager
The Executive Team

Key market activities

49
Focus on key growth provinces (Shandong,
Jiangsu,, Hunan, Zhejiang, Guangdong,
Guangxi) - To t a l popn 496m
Market expansion to continue with
China the key focus
Strengthen vertical Asian market from
Indonesia through China, and capitalise on
Indian distribution network
Build on International NGO Recognition (WHO,
UNITAID, CHAI, COGA , CSCCP) to build
acceptance and remove barriers to sale
Strengthen China Distribution
Capability via Strategic Partnership
with Dalton Bio
Target Govt and NGO funded
programs in addition to Zimbabwe,
Vietnam, Mexico and Uzbekistan
Growth Strategies

50
Developing strategic partnerships for
complementary woman’s health services
Focus on countries with limited or nil
cervical screening capability
Expand product portfolio to include Dalton
Bio HPV related IVD products DNA tests,
including HPV DNA tests and self sampling
Capitalise on global focus on AI
enabled cervical cancer technologies –
e.g. WHO
Reduce SUS and Device COGS and
increase profitability
Growth Strategies (cont.)

51
FY2026 active markets - at a glance (PSP = Public Screening Program)
Mexico
TRU sales
China:
TRU sales
(through SWXT and Dalton
distribution network)
India:
TRU sales
Dalton sales
Vietnam
PSP
Indonesia
TRU sales
Zimbabwe PSP
Uzbekistan
PSP
Eswatini PSP
Singapore, Malaysia,
Thailand, TRU sales

52
Key market China accounted for over 85% of global sales and exceeded
budget in FY25 and is now poised for expansion in 6 key provinces
•Key provinces for growth: TruScreen’s China distributor Beijing Siweixiangtai
Technology Co Ltd (SWXT) is targeting 6 key provinces for growth in FY26 -
Guangxi, Jiangsu, Hunan, Zhejiang, Shanghai and Guangdong. These provinces
have a combined population of 496 million, and an addressable screening market
of approximately 124 million women.
•TruScreen unaffected by US and China proposed tariff regimes: TruScreen
markets both an Australian and a Made in China device, providing a dual product
strategy in the key China market, with preferential market access for China
manufactured products
•30% increase in SUS Pull Through: Consumable Single Use Sensor (SUS) pull
through per month per device has reached peak of 142 SUS per month per device,
an increase of 30 % over 12 months.
•Software Upgrade: China’s NMPA registration variations have been approved and
software upgrade on Chinese devices has commenced. The upgrade will improve
user experience for clinicians and extend the device’s in-use service interval.
CHINA
477 million
women of
screening age*

53
•Private Sector Expansion: SWXT targeting of the growing China private health sector including private clinic and Health
Check Centre approvals in Jiangsu and Shenzhen, and entry into the Luxury Hospital and Traditional Chinese Medicine
Hospital sectors.
•Public Health Insurance: In addition to having 11 provinces with approved pricing for TruScreen, Beijing has awarded
public health insurance reimbursement for eligible TruScreen patients. Shanghai has completed the final round of
evaluation for public health insurance reimbursement and once he administrative processes for this are formalised sales
are expected to grow rapidly in this province.
In April 2025 TruScreen and SWXT planned the expansion of
TruScreen sales in China. From left to right: Mr Li, partner SWXT,
Marty Dillon, CEO TruScreen, Miss Su Siming, Managing Director
SWXT, Tony Ho, Chair TruScreen and Mr Wang, SWXT manager of
TruScreen business in China
hospitals have installed
TruScreen and actively use it
for cervical cancer
screening
hospitals have received
TruScreen approval, awaiting
tender completion
tenders won and awaiting
hospital installation
103
21
8
Currently in China:
=132

54
TruScreen selected to screen 260,000 women in Ho Chi Minh City and adoption
in Vietnam picks up pace – expected to be second largest market in FY2026
VIETNAM
36 million
women of
screening age*
5-year program to screen 260,000 women for cervical cancer in Ho Chi Minh City launched July 2025
Following the signing of a Memorandum of Understanding with the Ho Chi Minh City Public Health
Association and Gorton Health Services (Truscreen’s Vietnam distributor) in November, TruScreen has
been selected as the primary screening methodology for the capability of its unique, AI-enabled real time
cervical cancer screening technology to assist the Government of Vietnam achieve its goal of screening
60% of women aged 30 to 54 for cervical cancer (currently only 25% screened).
Public Hospital Adoption
In January 2025 Professor Michael
Campion presented at Tu Duc
Hospital in Ho Chi Minh City, leading
to 6 major Ho Chi Minh City hospitals
agreeing to adopt and install
TruScreen.
April 12 2025. TruScreen Chair Tony Ho, President of the Ho Chi
Minh City Public Health Association Dr Le Truong Giang and
Managing Director of Gorton Health Services Mr An Trang sign
the formal agreement to conduct a 260,000 women screening
program in Ho Chi Minh City.

55
TruScreen re-enters India with appointment of Renovate
Biologicals Pvt Ltd in April 2025
INDIA
468 million
women of
screening age*
India holds one-sixth of the world's population and one woman dies from cervical cancer
every eight minutes in the country. The cervical cancer screening rate is only 2%, and India’s
National Academy of Medical Sciences (NAMS) has recently set a target of 70% by 2030.
First sales have been completed, and TruScreen has already been used in 1800 women
program in Ladakh, NW India. The appointment of Renovate Biologicals now gives TruScreen
distribution capability in 3 of the 4 most populous countries in the world - China, India and
Indonesia. In addition to the distribution of TruScreen devices and SUS’s, TruScreen will also
commence distribution of Dalton Bio’s HPV IVD products in India – the first market agreement
to be made as part of the Dalton Bio strategic alliance.
Marty Dillon with the Renovate Biologicals team in
Hyderabad, India, August 2025.

56
Indonesia product registration completed and distributor
appointed, with commercial activity commenced in May
2025
INDONESIA
96 million
women of
screening age*
•Distributor Appointed: Following the completion of product registration,
TruScreen appointed a new Indonesian medical products distributor PT Mawar
Mitra Medika with commercial sales commenced in the world’s largest Islamic
nation, with a population spread over 14,000 islands. TruScreen offers an ideal
solution to providing screening to a geographically dispersed and diverse
population.
•AI presentation by CEO to MOH officials and KOL’s. In December 2024,
TruScreen presented to an AI Health webinar organised by Austrade and the
Indonesian Ministry of Health. TruScreen was one of only two companies
invited to present at this webinar, a recognition of our growing reputation as a
leader in AI innovative health technology with a particular relevance to
emerging economies.

57
Mexico second largest market in FY2025, accounting for 7% of
sales – with major private health insurer opportunity in play
MEXICO
46 million
women of
screening age*
Mexico has approximately 46 million women of screening age*, and cervical
cancer is the second most prevalent cancer amongst women.
HPVcentre.net estimates that 9,400 women are diagnosed annually with
cervical cancer with a very high mortality rate of 46% - 4,300 deaths.
Mexico’s national regulator, COFEPRIS, approved TruScreen for use in the
public health sector in FY2024, allowing TruScreen’s distributor Sunbird S.A
de C.V. to target the wider public health sector (70.9% of the population
access the public health system).
Mexico represented TruScreen’s second largest market after China in
FY2025, with new device installations continuing. TruScreen is currently
awaiting the outcome of a tender for the Instituto Mexicano del Seguro
Social (IMSS) the largest social security and health institution in Mexico for
the use of an opto electrical medical device for a cervical cancer screening
program.

58
African opportunities progress, with Zimbabwe PSP expected to
launch Q3 FY2026
ZIMBABWE
5 million
women of
screening age*
Zimbabwe
Since 2022, TruScreen has screened 14,000 women in the Masvingo Province, Zimbabwe,
through a public screening program managed by the Zimbabwe National AIDS Council (NAC)
and the Ministry of Health and Childcare. Formal re-validation is being undertaken by the
Ministry of Health, in order to expand the program. The clinical component of this re-validation
has bene completed and the analysis of results is to be completed in September 2025.
With limited pathology services and no nationwide recall system for follow-up appointments,
traditional screening methods such as cytology are not suitable for Zimbabwe’s population.
TruScreen, which enable a ‘see and treat’ screening service, is ideally suited to fill the gap in
Zimbabwe’s women healthcare system.
Eswatini
In May 2025, TruScreen and the Baylor Foundation Eswatini agree on the validation and initial
product training for TruScreen to be used for a pilot program to screen women in Eswatini
(formally Swaziland). Co-funding is being sought to replace the cancelled USAID funding
component.
E S WAT I N I
390,000
women of
screening age*

59
*Women aged 15-64 years as detailed in the World Fact Book : https://www.cia.gov/the-world-
factbook/
1
Xiao, F., Sui, L. Evaluation of a real-time optoelectronic method for the detection of cervical
intraepithelial neoplasia and cervical cancer in patients with different transformation zone
types.Sci Rep14, 27220 (2024). https://doi.org/10.1038/s41598-024-78773-w
2
Alhudhud, M., Maqsood, S., Hussein, M.E.et al.Cervical cancer screening: a comparative
study of TruScreen vs. Pap Smear.BMC Women's Health25, 198 (2025).
https://doi.org/10.1186/s12905-025-03733-z
3
Gao S, Tian Y, Song F, Wang J. Assessment of the Real-Time Photoelectric Detection Device
(TruScreen) in Screening for Cervical Precancerous Lesions in Middle-Aged Women: An
Observational Study.Risk Manag Healthc Policy. 2025;18:1783-1791
https://doi.org/10.2147/RMHP.S524022
References

60
Disclaimers
This presentation has been prepared by TruScreen Group Limited (the “Company”) and is dated 25 August 2023. This presentation contains summary information about the Company
and its activities which is current as at the date of this presentation. The information in this presentation is of a general nature and does not purport to be complete nor does it contain
all the information which a prospective investor may require in evaluating a possible investment in the Company. This presentation should be read in conjunction with the Company’s
annual report, market releases and other periodic and continuous disclosure announcements, which are available at www
.nzx.com. This presentation does not constitute an offer,
advertisement or invitation in any place in which, or to any person to whom, it would not be lawful to make such an offer, advertisement or invitation.
Not financial product advice
This presentation is for information purposes only and is not financial or investment advice or a recommendation to acquire the Company’s securities, and has been prepared without
taking into account the objectives, financial situation or needs of prospective investors. Before making an investment decision, prospective investors should consider the
appropriateness of the information having regard to their own objectives, financial situation and needs and consult a financial adviser, solicitor, accountant or other professional
adviser if necessary.
Past performance
Any past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance. No
representations or warranties are made as to the accuracy or completeness of such information.
Future performance
This presentation includes certain “forward-looking statements” about the Company and the environment in which the Company operates. Forward-looking information is inherently
uncertain and subject to contingencies, known and unknown risks and uncertainties and other factors, many of which are outside of the C o m p a ny ’s control, and may involve
significant elements of subjective judgement and assumptions as to future events which may or may not be correct. A number of important factors could cause actual results or
performance to differ materially from any forward-looking statements. No assurance can be given that actual outcomes or performance will not materially differ from the forward-
looking statements. The forward-looking statements are based on information available to the Company as at the date of this presentation. Except as required by law or regulation
(including the Listing Rules), the Company undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results
or otherwise.